Generate QR code
Open Access
Subscription Access
The influence of polygenic risk values on the development of dementia and on the dynamics of cognitive functions in patients with varying degrees of cognitive decline.
https://doi.org/10.25557/2073-7998.2025.12.154-156
Abstract
Patients with mild cognitive impairment (MCI) are at high risk of disease progression to Alzheimer’s disease (AD). Identifying genetic risk factors, such as the ε4 allele of the APOE gene, biomarkers corresponding to the early stages of AD, and assessing polygenic risk (PRS) with the potential for further stratification of patients into risk groups, may aid in predicting disease progression and prevention. The aim of this study is to develop a molecular method for analyzing genetic markers to assess the impact of polygenic risk values on the development of dementia and the dynamics of cognitive functions in patients with varying degrees of cognitive decline. A biochip was developed for the analysis of 21 risk markers and the ε2/ε3/ε4 alleles of the APOE gene. PRS values corresponding to the fourth quartile, as well as the presence of APOE-ε4, showed a significant association with an increased risk of developing dementia. PRS positively correlated with tTau and pTau181 and negatively correlated with the Aβ42/Aβ40 ratio. APOE-ε4 carriers had higher levels of tTau and pTau181 and lower levels of Aβ42 and Aβ42/ Aβ40. Concentrations of IP-10, FGF-2, and VEGF were significantly associated with the APOE genotype. Patients with the APOE ε4/ε4 genotype exhibited lower baseline cognitive scores and negative cognitive dynamics. The lack of a significant association between PRS and cognitive function dynamics may be due to timely provision of appropriate medical care for the prevention of cognitive impairments.
Keywords
dementia,
Alzheimer’s disease,
neurodegeneration,
mild cognitive decline,
polygenic risk,
biochip,
single nucleotide polymorphisms,
genetic markers
Supporting agencies: This research was funded by the Moscow Centre for Innovative Technologies in Healthcare (Agreement No. 0803-4/23-1NIR).
About the Authors
E. D. Fedoseeva
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Россия
Россия
A. Yu. Ikonnikova
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Россия
Россия
M. A. Emelyanova
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Россия
Россия
O. V. Antonova
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Россия
Россия
M. A. Filippova
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Россия
Россия
I. O. Morozova
Mental Health Clinic No. 1 named after N.A. Alekseev
Россия
Россия
A. B. Berdalin
Mental Health Clinic No. 1 named after N.A. Alekseev
Россия
Россия
V. M. Ushakova
Mental Health Clinic No. 1 named after N.A. Alekseev
Россия
Россия
A. G. Zeltser
Mental Health Clinic No. 1 named after N.A. Alekseev
Россия
Россия
T. S. Syunyakov
Mental Health Clinic No. 1 named after N.A. Alekseev
Россия
Россия
N. G. Osipova
Mental Health Clinic No. 1 named after N.A. Alekseev
Россия
Россия
Y. A. Zorkina
Mental Health Clinic No. 1 named after N.A. Alekseev; V.P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology
Россия
Россия
O. V. Abramova
Mental Health Clinic No. 1 named after N.A. Alekseev; V.P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology
Россия
Россия
D. S. Andreuyk
Mental Health Clinic No. 1 named after N.A. Alekseev
Россия
Россия
A. G. Ochneva
Mental Health Clinic No. 1 named after N.A. Alekseev
Россия
Россия
K. A. Pavlov
Mental Health Clinic No. 1 named after N.A. Alekseev
Россия
Россия
V. B. Savilov
Mental Health Clinic No. 1 named after N.A. Alekseev
Россия
Россия
K. P. Soloveva
Mental Health Clinic No. 1 named after N.A. Alekseev
Россия
Россия
M. V. Kurmishev
Mental Health Clinic No. 1 named after N.A. Alekseev
Россия
Россия
O. A. Karpenko
Mental Health Clinic No. 1 named after N.A. Alekseev
Россия
Россия
A. V. Andryushchenko
Mental Health Clinic No. 1 named after N.A. Alekseev
Россия
Россия
G. P. Kostyuk
Mental Health Clinic No. 1 named after N.A. Alekseev
Россия
Россия
A. Yu. Morozova
Mental Health Clinic No. 1 named after N.A. Alekseev; V.P. Serbsky Federal Medical Research Centre of Psychiatry and Narcology
Россия
Россия
D. A. Gryadunov
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
Россия
Россия
References
1. Studart A. Neto, Nitrini R. Subjective cognitive decline: The first clinical manifestation of Alzheimer’s disease? Dement Neuropsychol. 2016;10(3):170-177. doi: 10.1590/S1980-5764-2016DN1003002.
2. Litvinchuk A., Suh J.H., Guo J.L., et al. Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist. Neuron. 2024; 112(3):384-403.e8. doi: 10.1016/j.neuron.2023.10.023
Review
For citations:
Fedoseeva E.D., Ikonnikova A.Yu., Emelyanova M.A., Antonova O.V., Filippova M.A., Morozova I.O., Berdalin A.B., Ushakova V.M., Zeltser A.G., Syunyakov T.S., Osipova N.G., Zorkina Y.A., Abramova O.V., Andreuyk D.S., Ochneva A.G., Pavlov K.A., Savilov V.B., Soloveva K.P., Kurmishev M.V., Karpenko O.A., Andryushchenko A.V., Kostyuk G.P., Morozova A.Yu., Gryadunov D.A. The influence of polygenic risk values on the development of dementia and on the dynamics of cognitive functions in patients with varying degrees of cognitive decline. Medical Genetics. 2025;24(12):154-156. (In Russ.) https://doi.org/10.25557/2073-7998.2025.12.154-156
Views:
13
JATS XML
Email this article 